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ABSTRACT
Treatment for diabetic macular edema (DME)
is continuously evolving with the advent
of pharmacologic therapies. Focal laser
photocoagulation remains the historical
standard of care; however, a new wave of
studies is rapidly emerging that shows the
benefit of intravitreal antivascular endothelial
growth factor medications and corticosteroids.
The goal of this review is to compare the various
treatment options for DME, and include data
from the most recent clinical trials of therapies
for this complex condition.
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INTRODUCTION
Diabetic macular edema (DME) is a primary cause
of visual loss in diabetic patients in the working
age population of the US [1, 2]. The Early
Treatment Diabetic Retinopathy Study (ETDRS)
defined macular edema as the thickening of the
retina and/or hard exudates within 500 lm of the
center of the macula [3]. In the Wisconsin
Epidemiologic Study of Diabetic Retinopathy
(WESDR), the 10-year rate of developing DME
was 20.1% in patients with type 1 diabetes and,
in patients with type 2 diabetes, it was 25.4% for
those treated with insulin, and 13.9% for those
not treated with insulin [4]. The goal of this
review is to compare the various treatment
options for DME, and include data from the
most recent clinical trials of therapies for this
complex condition.
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METHODS
The various treatment modalities for DME and
the data from clinical trials were obtained by a
PubMed search using the above keywords.
Randomized, controlled trials that focused on
treatment of DME from 1970 to 2011 were
included in this review.
PATHOGENESIS
The pathogenesis of DME involves both
systemic and local risk factors. These risk
factors may alter the blood–retina barrier and
allow the leakage of proteins and fluid into the
macula [5]. Systemic risk factors associated with
DME include age, male gender, systolic blood
pressure, hyperlipidemia, proteinuria, insulin
use, diuretic use, a longer duration of diabetes,
higher glycosylated hemoglobin, and
pan-retinal photocoagulation (PRP) [5–8].
Local factors that may influence DME
include angiogenic factors, such as vascular
endothelial growth factor (VEGF), protein
kinase C (PKC), prostaglandins, growth
hormone, and the anatomy of the posterior
hyaloid face [9–11].
DIAGNOSIS
Clinically-significant macular edema (CSME) [3]
is defined as one or more of the following:
retinal thickening at or within 500 lm of the
center of the macula; hard exudates at or within
500 lm of the center of the macula, if associated
with adjacent retinal thickening; or a zone or
zones of retinal thickening one disc area in size,
at least part of which is within one disc
diameter of the center of the macula (Fig. 1).
This definition primarily refers to eyes eligible
for laser photocoagulation. With the advent of
pharmacotherapy (anti-VEGF agents or
corticosteroids) DME is more appropriately
defined as center-involved versus non-center
involved, with most cases of center-involved
macular edema appropriately eligible for
treatment with pharmacotherapy [12].
Intravenous fluorescein angiography (FA) and
optical coherence tomography (OCT) can assist
in the evaluation of DME [13]. Angiographic
findings reflect changes in vessel permeability
and patency [14]. FA assists in identifying areas
of macular edema, leakage, neovascularization,
and nonperfusion [15]. OCT is a useful tool for
the detection and monitoring of DME [16].
There exists a weak-to-modest correlation
between OCT-measured center-point thickness
and visual acuity [17, 18].
MANAGEMENT
The treatment of DME is focused on optimizing
systemic risk factors and use of laser,
pharmacologic, or surgical modalities to
Fig. 1 Fundus photo of CSME. CSME clinically signiﬁcant
macular edema
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reduce leakage into the macula and subsequent
macular edema [19].
Systemic Therapies
The United Kingdom Prospective Diabetes
Study (UKPDS) of type 2 diabetics [20], the
Diabetes Control and Complications Trial
(DCCT) [21, 22] of type 1 diabetics, and the
WESDR [23] established that a higher level of
glycosylated hemoglobin is a risk factor for DME.
The DCCT and UKPDS established that intensive
control of blood glucose should be a goal for
almost all patients with diabetes [20, 22]. The
intensive control group of the DCCT had a trend
toward less DME that did not reach statistical
significance. The UKPDS showed that superior
control of blood glucose and systemic
hypertension led to a lower rate of micro-vascular
complications [20, 24]. One study showed that
treatment of hyperlipidemia in patients with
macular edema and hard exudates resulted in
improvement or stability of visual acuity [25].
Treatment of renal dysfunction or smoking
cessation has not been proven to have a direct
benefit on DME; however, they are still
encouraged for diabetic patients.
PKC
The effect of VEGF on retinal vascular
permeability appears to be mediated
predominantly by the beta-isoform of PKC [9].
Ruboxistaurin (RBX) is an orally administered,
isoform-selective inhibitor of PKC-beta.
Animal models of diabetic retinopathy (DR)
and patients with diabetes-induced retinal
hemodynamic abnormalities have achieved
beneficial effects from the use of RBX [26]. In
a study by Aiello et al. [27] in treatment
naive DME patients, fewer eyes in the RBX
group (26.7%) required initial focal/grid
photocoagulation versus the placebo group
(35.6%; P = 0.008).
Cyclooxygenase Isozyme-2 Inhibitors
Inflammation plays a role in DME and
chronic inflammation has been shown to be
mediated, in part, by the cyclooxygenase (COX)
isozymes localized in the retina [28, 29].
Immunohistochemistry studies and animal
models of retinopathy have shown the efficacy
of COX-2 inhibitors [30–32]. In a prospective,
randomized, multicenter trial, celecoxib did not
show evidence of benefit as compared to laser
treatment. However, participants assigned to the
celecoxib group were more likely to have a
reduction in fluorescein leakage [33]. Potential
side effects of COX-2 inhibitors include allergic




The mechanism of action of laser
photocoagulation is unknown. The possible
explanations include laser-induced destruction
of the oxygen-consuming peripheral retina and
increased diffusion of oxygen through the laser
scars to the inner retina [34]. The ETDRS was
carried out, in part, to help understand the
effectiveness of photocoagulation in the
management of DME. The ETDRS used FA to
help direct laser photocoagulation treatment of
DME [35]. Treatable lesions were defined as
discrete angiographic points of retinal
hyperfluorescence or clinical points of focal
leakage between 500 and 3,000 lm from the
center of the fovea center considered to produce
retinal thickening or hard exudates; focal areas
of leakage between 300 and 500 lm from the
center of the macula causing retinal thickening
and hard exudates that persisted after a first
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treatment, and visual acuity of 20/40 or worse;
areas of diffuse leakage within the retina,
including microaneurysms, intraretinal
microvascular abnormalities (IRMA), and a
diffusely-leaking macular capillary bed; and
thickened avascular zones (except for the
foveal avascular zone). The ETDRS has
described two methods of treatment with laser
photocoagulation: focal or grid-pattern [35].
Focal photocoagulation consisted of whitening
or darkening of microaneurysms and areas of
focal fluorescein leakage with 50–200 lm laser
spots. Grid-pattern photocoagulation consisted
of light burns with a spot size of 50–200 lm,
spaced at least one spot size apart in an area
more than 500 lm from the foveal center and
the optic disc. Retreatment was carried out if
CSME was present at the 4-month follow-up
visit. FA was performed to detect new or residual
areas of focal or diffuse leakage. Focal leaks
within 500 lm from the center were treated if
the visual acuity was worse than 20/40, and if
such treatment could be performed without
significant risk to the center of the fovea [35].
Benefits of Laser Photocoagulation
The beneficial effect of immediate focal
photocoagulation was most pronounced for
patients with CSME (Fig. 2). The benefit of
treatment was present regardless of initial
visual acuity. Eyes with better visual acuity
had a better prognosis. In eyes with an initial
visual acuity of 20/40 or worse, an
improvement of one or more lines occurred
more frequently in treated than deferral eyes
[3]. Improvements of three or more lines of
visual acuity occurred infrequently. Patients
with macular edema and mild-to-moderate
nonproliferative DR (NPDR) benefited most
from immediate focal treatment and PRP
Fig. 2 Fundus photo (a) and baseline OCT scan (b) of
patient with CSME. The patient underwent laser
photocoagulation and there was partial resolution of
macular edema as noted in follow-up fundus photo
(c) and OCT (d). CSME clinically signiﬁcant macular
edema, OCT optical coherence tomography
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could be deferred until the development of
more severe retinopathy [3]. This treatment
strategy decreased the risk of a loss of
15 letters on the ETDRS chart (defined as a
moderate visual loss) by 50% compared with
eyes that did not receive laser treatment [3]. The
incidence of moderate visual loss at 2 years was
7% in the immediate laser treatment subgroup
compared to 16% in the deferral of
photocoagulation subgroup.
Adverse Effects of Laser Photocoagulation
Laser photocoagulation of the macula can cause
chorioretinal scars to expand up to 300% and
produce dense focal scotomas [36]. Other
potential adverse effects include reduced color
vision, choroidal neovascularization, retinal
pigment epithelium (RPE) fibrous metaplasia,
and inadvertent photocoagulation of the center
of the macula [34].
Alternative Laser Delivery Systems
Alternative laser delivery systems are being
developed to reduce complications of focal
photocoagulation. The micro-pulsed laser
system is able to achieve the desired benefits
by delivering energy as a train of short bursts to
the RPE with sufficient time between bursts
to allow the heated tissue temperature to return
to normal. This technique reduces collateral
damage significantly and decreases the risk of
expansion of retinal scars [37]. Moorman and
Hamilton [38], using a grid of sub-threshold
burns with a micro-pulsed diode laser (100 ls in
200 ms, or 5% duty cycle), demonstrated
resolution of macular edema in 57% of
diabetic eyes followed for 6 months.
Solid-state green pattern-scanning laser
(PASCAL) with a short-duration (0.01 s) has
also shown comparable results with standard
focal laser treatment for DME after a 4-month
follow-up [39]. Furthermore, to improve the
treatment accuracy and localization of retinal
lesions, a navigated laser (NAVILAS; OD-OS
GmbH, Teltow, Germany) photocoagulator has
been developed [40]. It consists of a retinal
eye-tracking laser delivery system with
integrated digital fundus imaging that allows
overlay of a treatment plan, based on either
fundus photography or FA, onto a real-time
image of the patient’s retina. This system uses a
diode-pumped solid-state laser (532 nm) and
automatically advances the aiming beam from
the marked site to the next after each
photocoagulation spot until the treatment
plan is completed. The other advantages are: a
larger area of the retina can be visualized than
with a slit lamp, images are reflex free, infrared
fundus illumination, no requirement for
contact lens use or topical anesthesia during
the procedure, and the availability of an
immediate detailed report.
Pharmacologic Treatments
Although focal laser photocoagulation per
ETDRS was successful in reducing the rates of
visual loss due to DME, many patients did not
recover lost vision and there was a subset of
patients who were unresponsive to this therapy
[41]. This led to the use of intraocular
pharmacologic agents for management of
DME [41]. Pharmacologic treatments are
typically administered in an outpatient setting
with topical anesthesia and a 27 or 30 G needle
is introduced into the vitreous cavity of the eye,
via the pars plana, to deliver the medication.
Corticosteroids
Corticosteroids decrease the release of
prostaglandins and inhibit the expression of
the VEGF gene [42, 43]. These antiinflammatory
and anti-VEGF properties may be able to reduce
breakdown of the blood–retina barrier.
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The various routes used for corticosteroids
delivery in the treatment of DME include
periocular injection, intravitreal injection, or
via the implantation of a bioerodable or
nonbioerodable sustained-release device [41].
Intravitreal Injection
Initial reports by Jonas et al. [44] and Martidis
et al. [45] showed promising results using
intravitreal steroids for the management of
refractory DME. Subsequent studies by Massin
et al. [46] and Gillies et al. [47] demonstrated an
improvement in visual acuity, a reduction in
macular thickness, and a decreased necessity for
laser treatment in eyes treated with 4 mg of
intravitreal triamcinolone (IVT). The Diabetic
Retinopathy Clinical Research (DRCR) Network
initiated a trial that evaluated IVT in 1 and 4 mg
doses, compared with focal laser treatment over
2 years [48]. The study consisted of 840 eyes
randomized to these three arms. At 4 months,
both triamcinolone groups had a greater
improvement in visual acuity and macular
thickness than the focal laser group; however,
by 1 year, there was no difference between
groups. At 2 years, the focal laser group
demonstrated better visual acuity and macular
thickness results compared to the corticosteroid
groups. Furthermore, there was a fourfold
elevation in the intraocular pressure and rate
of cataract formation in the steroid groups
compared with the focal laser group [48].
Several other studies have attempted to
evaluate the benefit of IVT as an adjunct to
focal/grid laser treatment [49–51]. The DRCR
Network group, in a recent phase 3 study, showed
no overall difference in visual acuity between IVT
plus laser treatment (n = 203) and laser treatment
alone (n = 186) after 1 year; however, a subgroup
of pseudophakic eyes treated with combined
IVT/laser had better visual acuity results
compared with laser alone [52].
Extended-Release Delivery Systems
One potential drawback of intravitreal injection
is that the treatment effect typically wanes,
and patients that are initially responsive to
treatment may require repeated injections. An
extended-release product could reduce the risks
associated with repeated injections. Retisert
(Bausch & Lomb, Rochester, NY, USA) is
FDA-approved for the treatment of uveitis and
is designed to release 0.59 lg/day fluocinolone
acetonide [53]. It has been evaluated for the
treatment of DME and showed some promise in
reducing macular thickness in DME; however,
after 2 years, 80–90% of phakic patients
required cataract extraction and 15–20% of
patients required incisional glaucoma surgery
[53]. Hence, a polymer insert positioned in the
eye by intravitreal injection was developed that
releases 0.2 lg/day (low dose) or 0.5 lg/day
(high dose) fluocinolone acetonide [54].
A randomized phase 3 trial, Fluocinolone
Acetonide in Diabetic Macular Edema (FAME),
was conducted in eyes with persistent DME
despite laser treatment [55]. It showed a
15-letter improvement from baseline at 2 years
in 28.7% of low-dose, 28.6% of high-dose, and
16.2% of sham injection patients [55].
An intravitreous drug delivery system (DDS)
that delivers dexamethasone directly to the
posterior segment for 35 days is also being
developed [56]. A phase 2 clinical trial was
conducted which included patients with DR
retinal vascular occlusive disease, Irvine-Gass
syndrome, or uveitis. Patients receiving the
700-lg implant had a statistically significant
improvement in visual acuity of two or more
lines, and significant improvements in retinal
thickness and fluorescein leakage in comparison
to patients who did not receive the implant
[57]. An intraocular pressure elevation to
25 mmHg or more was noted at some point in
32 of 306 study eyes. All eyes with intraocular
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pressure elevation were controlled with the use
of topical antiglaucoma medications [57].
Adverse Effects of Corticosteroids
Cataracts and elevation of intraocular pressure
are the principal adverse effects from use of
ocular steroids [58]. Intravitreal injection and
implantable devices carry additional risks
associated with the injection and implantation
procedure, respectively [56, 59].
Anti-VEGF Therapies
Increased vascular permeability is a hallmark of
DME. In human eyes with DR, hypoxia causes
upregulation of VEGF production, and leads to
retinal capillary hyperpermeability [60]. The
anti-VEGF therapies available at this time
include: pegaptanib sodium, ranibizumab,
bevacizumab, and aflibercept [19].
Pegaptanib
Pegaptanib binds to the VEGF-165 isomer [61].
In a phase 2, double-masked, randomized,
controlled trial evaluating patients with DME,
the intravitreal pegaptanib (0.3 mg dose) group
had a statistically higher proportion of patients
with a gain of 10 or more letters in visual acuity
(34 vs. 10%) as well as a reduction in macular
thickness (-68 vs. ?4 lm) as compared to the
sham group at 9 months follow-up [62]. The
patients treated with pegaptanib were also less
likely to need repeat focal laser treatment at
follow-up.
Bevacizumab
Bevacizumab is a FDA-approved intravenous
chemotherapy for various cancers and consists
of recombinant humanized antibody directed at
all isoforms of VEGF-A [63]. The DRCR Network
group conducted a phase 2 study comparing
various treatment arms of bevacizumab
intravitreal injections (1.25 mg), with or
without focal photocoagulation, over
3 months in 121 eyes [64]. Compared with
laser treatment alone, eyes in the bevacizumab
groups had an improvement in visual acuity
after 3 months (-1 letter vs. ?5 and ?7 letters,
respectively). Several other studies [65–67] have
examined the effect of bevacizumab therapy on
DME in a noncomparative fashion (Fig. 3). The
Bevacizumab Or Laser Therapy (BOLT) was
designed to compare bevacizumab therapy
head-to-head with laser treatment for DME
[68]. The BOLT study consisted of 80 patients
who had previously received focal laser
treatment for DME. Patients were randomly
assigned to the bevacizumab arm, receiving
injections every 6 weeks for the first 3 months
and every 6 weeks as needed thereafter, and the
laser arm, receiving laser treatment as needed
every 4 months. The bevacizumab arm showed
a superior gain in visual acuity at 12 months
(?8 letters vs. -0.5 letters), and a greater
decrease in macular thickness (130 vs. 68 lm,
P = 0.06) [68].
Ranibizumab
Ranibizumab is a humanized antibody fragment
directed at all isoforms of VEGF-A [69]. It is an
FDA-approved intravitreal therapy for the
treatment of age-related macular degeneration
[70] and macular edema associated with retinal
vein occlusion [71]. In the Ranibizumab for
Edema of the mAcula in Diabetes-2 (READ-2)
study, intravitreal ranibizumab 0.5 mg alone, or
laser treatment alone, or a combination of
ranibizumab and focal laser treatment was
compared in 126 eyes. The ranibizumab group
had the superior visual outcome (a gain of
7.2 letters), while the laser group lost ETDRS
0.43 letters and the combination group gained
3.8 letters [72]. Another phase 2, randomized,
clinical trial, Ranibizumab in Diabetic Macular
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Edema Study (RESOLVE), compared 0.3 and
0.5 mg ranibizumab with sham injections for
the treatment of DME in 151 eyes [73]. Patients
received monthly injections for an initial
3 months, followed by a continuation of
monthly injections on an as-needed basis with
the opportunity for rescue focal laser treatment.
At 12 months, there was an improvement in
visual acuity in the ranibizumab group
(?10.3 letters) and reduction in macular
thickness (-194 lm) versus the sham group
(-1.4 letters and -48 lm, respectively). The
percentage of patients who gained at least 10
letters was significantly greater in the
ranibizumab group (60.8%) versus the sham
group (18.4%). The DRCR Network group has
also reported 1-year results of a phase 3,
randomized, controlled trial showing visual
acuity improvement was greater in
ranibizumab groups (?9 letters) versus the
laser-only treatment (?3 letters) and the
triamcinolone group (?4 letters) [52].
Recently, Genentech announced the 24-month
results from two phase 3, multicenter,
randomized, double-masked studies (RISE
n = 377; RIDE n = 382) designed to assess the
safety and efficacy of ranibizumab in patients
with DME [74]. In these studies, patients were
randomized to receive monthly injections of
ranibizumab or sham injections with macular
laser rescue-treatment available to all patients at
3 months. The results revealed a significant
percentage of patients in the ranibizumab
group (40%) had an improvement of at least
15 additional letters (3 lines) from baseline as
compared to the sham group (15%). These studies
also show that the benefit from ranibizumab was
as early as 7 days post first injection, and 60% of
the patients achieved visual acuity greater than or
equal to 20/40. Furthermore, approximately 4%
of the patients in the ranibizumab group
progressed to proliferative DR as compared to
13% in the sham group.
Aflibercept
Aflibercept is a fusion protein that binds to
VEGF-A and placental growth factor [75]. It has
a tighter binding affinity to VEGF compared
with the current anti-VEGF therapies [75]. The
DME and VEGF Trap-Eye: Investigation of
Clinical Impact (DAVINCI) trial investigated
the role of aflibercept in DME. In this trial,
aflibercept was given in 3 monthly loading
doses followed by either as-needed dosing or
Fig. 3 Baseline OCT scan (a) of patient with persistent
DME in spite of laser photocoagulation. The patient
underwent ﬁve intravitreal injections of bevacizumab at
6 weeks interval. There was a considerable resolution of
macular edema as noted in follow up OCT scan (b). DME
diabetic macular edema, OCT optical coherence tomography
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dosing every 8 weeks, and compared to macular
laser photocoagulation [76]. This phase 2 trial
showed aflibercept had superior visual
outcomes (?8.5 to ?11.4 letters) as compared
to laser photocoagulation (?2.5 letters;
P = 0.0085) at 6 months. A phase 3 trial of
Intravitreal Administration of VEGF Trap-Eye in
Patients With Diabetic Macular Edema (VISTA
DME) is currently underway [75].
Vitrectomy
There are several reports of an association
between DME and the anatomy of the
vitreoretinal interface [77, 78]. In one study,
the prevalence of posterior vitreous detachment
(PVD) was observed among 20% of the eyes
with CSME as compared to 55% of the
non-CSME group [77]. Furthermore,
vitreomacular separation was associated with
an increased rate of spontaneous resolution of
macular edema [11]. Thus, an attached posterior
hyaloid predisposes to the development of DME
(Fig. 4) and, hence, pars plana vitrectomy may
have a role in the treatment of DME [79–82].
Harbour et al. [83] reported a case series of seven
eyes with DME attributed to a thickened and
taut posterior hyaloid that underwent pars
plana vitrectomy. Visual acuity improved by
two or more lines in four eyes, and macular
edema resolved in four eyes and diminished in
two eyes. The DRCR Network group has also
reported the 6-month primary outcome and
1-year final follow-up results on visual
and anatomic outcomes after vitrectomy
performed without concomitant cataract
surgery in eyes with DME [84]. This
prospective, observational study consisted of
87 eyes with DME and vitreomacular traction
that underwent standard pars plana vitrectomy
with peeling of posterior hyaloid/epiretinal
membrane, and additional maneuvers based
on the investigator’s evaluation. At 6 months,
visual acuity improved by C10 letters in 38% of
eyes and the median OCT central subfield
thickness decreased by 160 lm (43% having
central subfield thickness \250 lm and 68%
Fig. 4 Fundus photo (a) and OCT scan (b) of patient with DME secondary to vitreoretinal interface disease. DME
diabetic macular edema, OCT optical coherence tomography
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having at least a 50% reduction in thickening),
as compared to baseline median visual acuity of
20/100 and median OCT thickness of 491 lm
[84]. Postoperative complications during the
6 months included retinal detachment (3 eyes),
endophthalmitis (1 eye), vitreous hemorrhage
(5 eyes), and elevated intraocular pressure
requiring treatment (7 eyes). Thus, vitrectomy
performed in eyes with DME reduces macular
thickening with a visual acuity improvement in
28–49% patients, and worsening in 13–31%.
Patients with macular ischemia, RPE atrophy,
subfoveal lipid, and a baseline visual acuity of
20/200 or less tended to respond less favorably
to surgery [85]. The expected complications
of vitrectomy include cataract progression,
vitreous hemorrhage, and retinal tear or
detachment [84, 86].
CONCLUSION
There has been considerable progress in
understanding the pathophysiology of DME
and the development of new therapies. Based
on various clinical and epidemiologic studies, it
is recommended for all patients with diabetes to
maintain good control of blood sugars, blood
pressure, and hyperlipidemia as determined by
their primary care physician. Focal or grid
photocoagulation remains the first-line
treatment in the majority of patients with
non-center-involved DME. In many patients
with center-involved DME, intravitreal
injection of anti-VEGF therapies is becoming
commonly used. Patients unresponsive to
anti-VEGF therapies may benefit from
intravitreal injection of triamcinolone or
possibly an extended-release steroid delivery
system to deliver corticosteroids to the
posterior segment. However, patients need to
understand the risks of these treatments,
especially with regards to cataract and
glaucoma. In patients with vitreoretinal
interface disease, vitrectomy with removal of
the posterior vitreous may be a viable option. As
new and improved therapies are continuously
developed, treatment paradigms will also
change, with DME patients being the ultimate
beneficiaries of these exciting developments.
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